---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-014226"
form_type: "8-K"
ticker: "IKT"
cik: "0001750149"
company_name: "Inhibikase Therapeutics, Inc."
filed_at: "2023-01-24T23:59:59+00:00"
generated_at: "2026-06-20T10:56:13.901297+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Inhibikase receives Nasdaq extension to July 24, 2023 to regain $1 minimum bid price compliance

## Summary
- Nasdaq granted additional 180-day period until July 24, 2023 to meet Minimum Bid Price Requirement.
- Compliance requires closing bid price at least $1.00 for 10 consecutive business days.
- Company previously disclosed deficiency on July 25, 2022; intends to cure via reverse stock split if needed.
- Failure to demonstrate compliance by July 24, 2023 will result in Nasdaq delisting notice, with appeal rights.

## SEC filing metadata
- accession: 0001193125-23-014226
- form_type: 8-K
- ticker: IKT
- cik: 0001750149
- company_name: Inhibikase Therapeutics, Inc.
- filed_at: 2023-01-24T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1750149/000119312523014226/0001193125-23-014226-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1750149/000119312523014226/d355336d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-014226
- JSON: https://secwatch.observer/filing/0001193125-23-014226.json
- Plain text: https://secwatch.observer/filing/0001193125-23-014226.txt

## Key facts
- Listing & Compliance Notices
  Inhibikase Therapeutics, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).
  - Exchange: nasdaq
  - Notice: extension granted
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2)
  source text: January 24, 2023, the Company received notice from Nasdaq indicating that, while the Company has not regained compliance with the Minimum Bid Price Requirement, Nasdaq has determined that the Company is eligible for an additional 180-day period, or until July 24, 2023, to regain compliance. According to the notice from Nasdaq, the Staff’s determination was based on (i) the Company meeting the continued listing requirement for the market value of its publicly held shares and all other Nasdaq initial listing standards, with the exception of the Minimum Bid Price Requirement, and (ii) the Company
  evidence_url: https://www.sec.gov/Archives/edgar/data/1750149/000119312523014226/0001193125-23-014226-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.